AVTX - Avalo Therapeutics Inc logo

Avalo Therapeutics Inc

AVTX

Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1ฮฒ-based treatments for immune-mediated inflammatory diseases. Its lead product, AVTX-009, is a humanized monoclonal antibody currently in Phase 2 trials for hidradenitis suppurativa.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$1today

Score Overview

1 Year
Score
Net Growth-28.21%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth0.00%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.9
Net Growth-18.91%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-98.91%
Rev Trend20%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-4x
Net Trend40%
Net Income Consistency
Rev Growth-94.88%
Rev Trend20%
Revenue Consistency
All Time
Scoreโ€”
Net Growth-7x
Net Trend36%
Net Income Consistency
Rev Growthโ€”
Rev Trend20%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Avalo Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. AVTX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-02
$ 14.99โ€”
1 Year2025-10-02
$ 13.0015.31%
5 Years2021-10-01
$ 6.48K-99.77%
10 Years2016-09-30
$ 12.18K-99.88%
All Time2015-11-13
$ 11.52K-99.87%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 59K-$ 100M$ 400M
2025$ 59K-$ 78M$ 98M
2024$ 441K-$ 35M$ 134M
2023$ 1M-$ 31M$ 7M
2022$ 18M-$ 41M$ 13M
2021$ 5M-$ 84M$ 54M
2020$ 6M-$ 63M$ 18M
2019$ 6M-$ 16M$ 11M
2018$ 18M-$ 40M$ 10M
2017$ 27M$ 11M$ 2M
2016$ 1M-$ 16M$ 5M
IPO2015-$ 10M$ 21M
AVTX - Avalo Therapeutics Inc logo

Avalo Therapeutics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 6M to $ 59K and net income went from -$ 63M to -$ 78M. Revenue increased in 1 of those 5 years; net income in 2.

Between 2015 and 2025, net income went from -$ 10M to -$ 78M. Revenue increased in 2 of those 10 years; net income in 4.

Avalo Therapeutics Inc currently holds a 5-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.

Membership

Explore AVTX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies